Consulting Reports
Ethical and Economic Issues in the Appraisal of Medicines for Ultra-rare (or Ultra-orphan) Conditions
13 January 2020
In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting…
Data Governance Arrangements for Real-world Evidence in Japan
12 September 2019
A new OHE Consulting Report describes the current status of real-world data in Japan, including core legislation and governance arrangements. The authors sought to understand how…
Unrelieved Pain in Palliative Care in England
2 September 2019
Although the quality of palliative care in England and the wider UK is regarded as excellent, many patients receiving palliative care die in pain. This new…
Public Preferences for Health Gains and Cures: A Discrete Choice Experiment
22 January 2019
Just published is a new OHE Consulting Report that explores society’s preferences across curative and non-curative therapies and large and small health gains.
Making the Most of Health Data to Deliver Pharmaceutical Innovation: What Are the Legal Barriers?
20 December 2018
OHE publishes a report on the legal barriers to the better use of health data to deliver pharmaceutical innovation.
Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS
29 August 2018
OHE Consulting produces a report on Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS.
The Impact of New Medicines in the NHS: 70 Years of Innovation
14 August 2018
This year marks the 70th birthday of the NHS. Our latest Consulting Report describes the most important new medicines as identified by experts.
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
3 July 2018
We conducted a literature review in order to identify whether long-term cancer survivors’ quality of life is comparable to that of the general population.
A Critique of Hill et al. (2018) on Estimated Costs of Production for the WHO Essential Medicines List
19 May 2018
OHE Consulting produces a report critiquing a paper by Hill et al. (2018) on estimated costs of production for the WHO Essential Medicines List.